Related Experiment Video
Updated: May 13, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Alpha-1 antitrypsin deficiency, a corporate perspective.
1Talecris Biotherapeutics, Research Triangle Park, North Carolina, USA. ldstern1215@gmail.com
COPD
|March 27, 2013
Summary
Best-in-class systems for alpha-1 antitrypsin (AAT) deficiency management have emerged. Future advancements in identifying, treating, and curing AAT patients require strong leadership and six key initiatives.
Area of Science:
- Pulmonology and Genetics
- Rare Disease Management
Background:
- Established systems involve AAT producers, specialty pharmacies, and patient advocacy groups like the Alpha-1 Foundation and AlphaNet.
- Recognized benefits include advancements in public policy, patient advocacy, research, medication adherence, patient identification, and health outcomes.
Purpose of the Study:
- To outline key initiatives for advancing the management of Alpha-1 antitrypsin (AAT) deficiency.
- To drive a significant improvement in disease state management for AAT patients.
Main Methods:
- Review and synthesis of current best-in-class systems in AAT management.
- Identification of critical areas for future development and leadership.
Main Results:
- Current systems demonstrate success in various aspects of AAT patient care.
- Six strategic initiatives are proposed to sustain and enhance best-in-class approaches.
Conclusions:
- Continued collaboration between industry and patient groups is crucial for AAT deficiency.
- Implementing the proposed initiatives will support the identification, treatment, and potential cure for AAT patients.
Related Concept Videos
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.